bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 4086: Critical roles of FRS2beta, a feedback inhibitor of ErbB-ERK signaling, for communication between cancer stem cells and their niche during mammary tumorigenesis
Authors: Machida Yukino , Kimura Natsuko , Tojo Arinobu , Akashi Ko-ichi , Saya Hideyuki , Kitabayashi Issay , Gotoh Noriko 
Published: July 2016

Abstract
Inflammatory microenvironment contributes to tumorigenesis. Although it is thought that breast cancer stem cells (CSCs) appear and grow in the inflammatory microenvironment that is called CSC niche, it remains largely unclear how it occurs. Here, we uncovered FRS2beta, a feed-back inhibitor of ERK activity in progenitor cells, plays critical roles for various cytokine production to increase progenitor cell- and CSC- state, and create the CSC niche. Expression levels of FRS2beta were increased in mammary tumors of MMTV-ErbB2 mice than in normal mammary tissues. Deficiency of FRS2beta greatly delayed mammary tumorigenesis, decreased mammosphere-forming ability and tumor stroma, a component of the CSC niche. Expression levels of various cytokines, including IGF1 and CXCL12, stemness- and stroma-inducing cytokines, respectively, were reduced in FRS2beta-mutant mammospheres, pre-cancerous mammary and tumor tissues. Furthermore, expression levels of FRS2beta were higher in CD44highCD24low CSCs-enriched population in patient-derived breast cancer tissues. Thus the mechanisms to maintain progenitor cell-state by prevention of excess ERK activity may permit production of various cytokines to create CSC niche, and allow appearance and growth of CSCs. These results suggest that treatment with MEK inhibitors may allow survival of CSCs, raising the risk of recurrence. We provide a rationale of combination therapy targeting both FRS2beta and MEK inhibitors to eradicate tumors.
Citation Format: Yukino Machida, Natsuko Kimura, Arinobu Tojo, Ko-ichi Akashi, Hideyuki Saya, Issay Kitabayashi, Noriko Gotoh. Critical roles of FRS2beta, a feedback inhibitor of ErbB-ERK signaling, for communication between cancer stem cells and their niche during mammary tumorigenesis. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4086.
Abstract 4088: Adipocytes-mediated autophagy activation and metabolic reprogramming promotes colon cancer survival
Authors: Wen Yang-an , Xiong Xiaopeng , Harris Jennifer , Zaytseva1 Yekaterina , Gao Tianyan 
Published: July 2016

Abstract
Obesity has been associated with increased incidence and mortality of a wide variety of human cancers including colorectal cancer. However, the molecular mechanism underlying the functional interaction between obesity and cancer remains elusive. Here, we demonstrated that adipocytes isolated from adipose tissues of colon cancer patients play an important role in promoting tumor cell survival and progression by altering cellular metabolism. In stage IV colon cancer cases, abundant adipocytes were found in close association with invasive colon cancer cells. Co-culture of adipocytes with colon cancer cells led to direct transfer of free fatty acids (FAs) released by the adipocytes to colon cancer cells. Uptake of FAs allowed the cancer cells to survive nutrient deprivation conditions by upregulating mitochondrial fatty acid β-oxidation, suggesting that FAs from adipocytes were used as an energy source by the cancer cells. In addition, we found that co-culture of adipocytes or treating cells with fatty acids induced autophagy in colon cancer cells as a result of AMPK activation. Inhibition of autophagy attenuated the ability of cancer cells to utilize FAs and blocked the growth promoting effect of adipocytes. Furthermore, we found that adipocytes induced dedifferentiation of tumor cells in primary colon cancer cells and mouse tumor organoids. Taken together, these results identify adipocytes as active contributors to the tumor microenvironment that promote tumor growth and survival by serving as an energy provider and a metabolic regulator for the embedded colon cancer cells.
Citation Format: Yang-an Wen, Xiaopeng Xiong, Jennifer Harris, Yekaterina Zaytseva1, Tianyan Gao. Adipocytes-mediated autophagy activation and metabolic reprogramming promotes colon cancer survival. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4088.
Abstract 4114: Blocking Ezrin can inhibit HGF/Met signaling-induced metastasis
Authors: Yu Yanlin , Huang Liping , Merlino Glenn 
Published: July 2016

Abstract
Hepatocyte Growth Factor (HGF) binds its receptor Met and induces autophosphorylation of MET, which in turn activate appropriate signaling pathways. Aberrant HGF/Met signaling promotes tumor progression by facilitating cell proliferation, migration, invasion, and metastasis. Previously, we found that constitutive HGF/Met signaling promotes melanoma metastasis through a nonautocrine mechanism in engineered mouse models (Cancer Res, 2002); however, the molecular mechanisms by downstream of HGF/Met signaling that induce metastasis are not known. We recently identified the cytoskeletal organizer Ezrin as a key metastatic regulator using an HGF transgenic mouse model (Nature Medicine, 2004), implicating Ezrin is in HGF/Met signaling-induced metastasis. We hypothesize that HGF/Met signaling promotes metastasis by regulating expression of Ezrin. To test hypothesis, we are: 1) evaluating the relationship between ezrin expression and HGF/Met signaling; 2) validating the role of Ezrin in HGF/Met signaling -induced metastasis; 3) elaborating mechanisms underlying this HGF/Met signaling-mediated regulation of Ezrin expression; 4) evaluating the clinical therapeutic utility of blockage of Ezrin function in preclinical mouse models. We found that HGF is able to stimulate the expression of Ezrin. Moreover, analysis of the established model systems with HGF and Met alone or HGF with Met demonstrated that Ezrin expression correlated with activated HGF/Met signaling, suggesting that HGF/Met signaling regulates the expression of Ezrin. Interestingly, we showed that HGF/Met signaling could activate transcription factor Sp1 through the MAPK pathway. We further found that activated Sp1 could directly bind to the promoter of the Ezrin gene and regulate the transcription of Ezrin. Notably, knockdown of Ezrin expression by shRNAs inhibited the metastasis induced by both HGF/Met autocrine and notautocrine signaling in syngeneic host and HGF GEM hosts. We also used small molecule drugs in preclinical mouse models to confirm that Ezrin is at least one of downstream molecules mediating HGF/Met signaling-induced metastasis in melanoma. We conclude that Ezrin is a key downstream substrate involved in the regulation of HGF/Met signaling-induced metastasis. We demonstrate a link between Ezrin and HGF/Met/MAPK/Sp1 activation in the metastatic process. Our data indicate that Ezrin represents a promising therapeutic target for patients with activated HGF/Met signaling.
Citation Format: Yanlin Yu, Liping Huang, Glenn Merlino. Blocking Ezrin can inhibit HGF/Met signaling-induced metastasis. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4114.
Abstract 4117: AMD070, a novel orally bioavailable CXCR4 inhibitor, inhibits the metastases of oral cancer via SDF-1/CXCR4 system
Authors: Kinouchi Makoto , Uchida Daisuke , Kuribayashi Nobuyuki , Wakui Takahiro , Kuribayashi Kyoko , Okubo Maki , Saito Masahiro , Masuyama Eri , Kawamata Hitoshi 
Published: July 2016

Abstract
We have demonstrated that the stromal cell-derived factor (SDF)-1/CXCR4 system is involved in metastatic processes in oral cancer. Moreover, we have also reported that blocking CXCR4 with AMD3100, a CXCR4 antagonist, may be a potent anti-metastatic therapy for CXCR4-related head and neck cancer. Recently, AMD070 has been described as a novel orally bioavailable inhibitor of CXCR4, being minimally invasive than AMD3100. In this study, we examined the effect of AMD070 on the SDF-1/CXCR4 dependent-metastases in oral cancer cells, B88-SDF-1, which express high levels of SDF-1 and CXCR4.
We examined the effect of CXCR4-specific antagonists, AMD3100 and AMD070 on the cell growth, cell migration and cell invasion of B88-SDF-1 cells. Both antagonists did not affect the anchorage-dependent growth of B88-SDF-1 cells, but did inhibit the SDF-1/CXCR4 dependent-migration of the cells. Moreover, AMD070 significantly suppressed anchorage-independent growth and invasion of B88-SDF-1 cells. Next we examined the effect of AMD070 to distant metastasis in vivo. Daily administration of AMD070 per os significantly inhibited the metastasis of B88-SDF-1 cells to the lungs of nude mice. These results indicated that AMD070 might be a novel orally bioavailable inhibitor on the metastases of oral cancer by the SDF-1/CXCR4 system.
Citation Format: Makoto Kinouchi, Daisuke Uchida, Nobuyuki Kuribayashi, Takahiro Wakui, Kyoko Kuribayashi, Maki Okubo, Masahiro Saito, Eri Masuyama, Hitoshi Kawamata. AMD070, a novel orally bioavailable CXCR4 inhibitor, inhibits the metastases of oral cancer via SDF-1/CXCR4 system. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4117.
Abstract 412: RNA-Seq provides cost-effective alternative for typing self-identifying antigens in immunotherapy patients
Authors: Robasky Kimberly , Powers Jason , Trapolsi Donald , Jasper Jeff , Brown Chad 
Published: July 2016

Abstract
The excitement surrounding immunotherapy is being driven by results in the clinic. Currently, autoimmunity is an unfortunate side-effect for a large fraction of those treated. Consequently, understanding how self-antigens are recognized is nearly as important as characterizing the immune repertoire for efficacious delivery of these promising new therapies. One approach to measuring the tumor immune environment is with RNA-Seq assays. Here we show that the genes responsible for presenting self-antigens (HLA Class I and Class II) can also be ascertained from RNA-Seq on total RNA. We present the detailed results from standard RNA-Seq pipeline analysis for 40 lymphoblastoid cell lines to achieve 91.3% overall concordance with “gold standard” typings. These samples were sequenced with 50bp paired-ends and approximately 30M reads. We additionally present RNA-Seq analysis results from calling HLA alleles on 15 replicate pairs of FFPE hepatic tumor samples, finding 88.33% overall replicate concordance with 2-digit precision, and 90% for Class I alleles. Finally, we present HLA-types on triplicates from 2 common breast cancer cell lines, MCF7 and T47D for loci HLA-A,-B,-C,-DRB1,-DQB1, with 90% overall replicate concordance. Emerging targeted DNA-Seq assays aimed at high-throughput clinical trials require high quality whole-blood samples that yield larger amounts of assay input material. Alternatively, the analyses presented here do not require HLA-region enrichment and thus can also be performed on legacy RNA-Seq data. Notably, the data here are generated from sample types and amounts that are more typical to a clinical oncology setting, and because it does not rely on targeted capture as do DNA-Seq assays, these analyses hold greater promise for assembling rare alleles and fusions.
Citation Format: Kimberly Robasky, Jason Powers, Donald Trapolsi, Jeff Jasper, Chad Brown. RNA-Seq provides cost-effective alternative for typing self-identifying antigens in immunotherapy patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 412.
Abstract 4124: Sub-cytotoxic concentrations of a novel polyphenol fatty acid ester derivative arrest breast cancer cell proliferation and metastasis
Authors: Fernando Wasundara , Coombs Melanie R. Power , Hoskin David W. , Rupasinghe H. P. Vasantha 
Published: July 2016

Abstract
In this study, the antiproliferative and antimetastatic properties of phloridzin docosahexaenoate (PZ-DHA), a novel polyphenol fatty acid ester derivative, were explored using in vitro and in vivo models of mammary carcinoma. PZ-DHA combines phloridzin (PZ, a dihydrochalcone found in apple peels) with docosahexaenoic acid (DHA, an omega-3 fatty acid). The regioselective acylation reaction was catalyzed by lipase B enzyme from Candida antarctica. PZ-DHA-induced selective cytotoxicity towards breast cancer cells (triple-negative mammary carcinoma cells, MDA-MB-231, MDA-MB-468, and 4T1; estrogen receptor-positive mammary carcinoma cells, MCF-7 and T-47D) was observed compared to human mammary epithelial cells (HMECs and MCF 10A) using the MTS assay. Significantly less (p&lt;0.05) cytotoxicity of PZ-DHA for normal cells was also confirmed using flow cytometric analysis of annexin-V-FLUOS/propidium iodide-stained MCF 10A and human dermal fibroblasts compared to MDA-MB-231 cells. Flow cytometric analysis of Oregon Green 488-stained MDA-MB-231 cells showed an antiproliferative effect of PZ-DHA at sub-cytotoxic concentrations (10 to 30 μM). Cell cycle analysis showed that MDA-MB-231 replication was arrested at the G2/M phase of the cell cycle following treatment with PZ-DHA at sub-cytotoxic concentrations. PZ-DHA suppressed the migration of MDA-MB-231 and 4T1 cells in vitro in wound healing and cell migration assays. Reduced expression of proteins (β-catenin, slug, Zinc finger E-box-binding homeobox 1, vimentin and matrix metalloproteinase-2) involved in the epithelial-to-mesenchymal transition was demonstrated by western blot analysis of PZ-DHA-treated MDA-MB-231 cell lysates. Finally, 4T1 tumor bearing-female BALB/c mice that received intra-peritoneal injections of PZ-DHA showed a significant reduction (p&lt;0.05, n = 9) in primary tumor volume at the mammary fat pad and fewer metastatic lesions in the lungs compared to the saline-treated control mice, suggesting an in vivo antimetastatic effect of PZ-DHA. In conclusion, findings of this study reveal that PZ-DHA suppresses mammary carcinoma cell proliferation and metastasis, suggesting a potential clinical application to prevent breast cancer progression in patients.
Citation Format: Wasundara Fernando, Melanie R. Power Coombs, David W. Hoskin, H. P. Vasantha Rupasinghe. Sub-cytotoxic concentrations of a novel polyphenol fatty acid ester derivative arrest breast cancer cell proliferation and metastasis. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4124.
Abstract 4126: An anti-CD4 antibody protects mice from anti-PD-1/PDL-1 antibody-induced fatal anaphylaxis and shows potent anti-metastatic activity in the 4T1 spontaneous metastasis model
Authors: Ito Satoru , Yokochi Shoji , Ishiwata Yoshiro , Ueha Satoshi , Shand Francis , Matsushima Kouji 
Published: July 2016

Abstract
[Introduction]
We previously reported that an α-CD4 depleting monoclonal antibody (mAb) has very potent anti-tumor effects in several murine tumor models, particularly when combined with α-PD-1/L1 mAbs (Cancer Immunol. Res. 3: 631-640; 2015). Here we examined the effect of this α-CD4 mAb on 4T1 murine mammary tumors, which undergo spontaneous metastasis from an orthotopically transplanted site to the lung.
[Methods]
4T1 tumor cells (1 × 105) were injected into the mammary fat pad of female BALB/c mice and primary tumor volume was measured every 2-3 days. Spontaneous lung metastasis was quantitated by removing the lungs, fixing them in Bouin's fixative, and counting the number of metastatic nodules on the surface of lung.
[Results]
Administration of α-CD4 mAb (clone GK1.5; days 5 and 9 after tumor inoculation) significantly inhibited 4T1 lung metastasis (n = 10) without affecting primary tumor size. α-PD-1 and α-PD-L1 mAbs had minimal effects on primary tumor growth and metastasis. However, administration of α-PD-1 or α-PD-L1 mAbs triggered an IgG1-mediated fatal anaphylactic reaction upon the third or fourth administration. Interestingly, the anaphylactic reaction was completely prevented by co-administration of the α-CD4 mAb.
[Discussion]
Based on these results, α-CD4 mAb may be useful for preventing metastasis associated with advanced cancer. In addition, α-CD4 mAb appeared to be protective against the IgG-mediated anaphylactic reaction and autoimmune-like side effects that are associated with α-PD-1/α-PD-L antibody administration-induced enhanced B-cell immunity. Increased myelopoiesis due to high G-CSF production by 4T1 cells may have contributed to the anaphylactic reaction.
Citation Format: Satoru Ito, Shoji Yokochi, Yoshiro Ishiwata, Satoshi Ueha, Francis Shand, Kouji Matsushima. An anti-CD4 antibody protects mice from anti-PD-1/PDL-1 antibody-induced fatal anaphylaxis and shows potent anti-metastatic activity in the 4T1 spontaneous metastasis model. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4126.
Abstract 413: Validation of an antibody independent tool for patient selection: RNA in situ hybridization detects Met expression levels predictive for response to Met inhibition by Bay 853474
Authors: von Ahsen Oliver , Krahn Thomas , Schatz Christoph 
Published: July 2016

Abstract
This study was performed in order to validate RNA in situ hybridization (RNA ISH) as tool for patient selection. Met expression was analyzed in a matched sample set of FFPE versus fresh frozen tumor samples comprising 20 cases of gastric cancer. Classical immunohistochemistry using the antibody SP44 and RNA ISH (RNAscope by ACD) were used to detect c-met expression in FFPE material. The results were confirmed by sandwich-immunoassays on Met and its phosphorylation on tyrosine 1349 (MSD) as well as mass spectrometry. The level of functional relevance was determined by testing a set of cell lines comprising some with genomic amplification of the met gene as well as some non-amplified lines showing different expression levels. Among gastric cancer cell lines only those with met amplification respond to treatment with the small molecule Met inhibitor Bay 853474. The cell line result generates a responder hypothesis that can be used to define a cutoff for clinical samples. 2 of the 20 investigated clinical samples were shown to have high level Met expression by RNA ISH and IHC that could be confirmed by sandwich-immunoassays also showing high level of functional activity by phosphotyrosine 1349. Met expression in these cases was also confirmed by mass spectrometry. Expression levels and functional activity in these 2 cases were in the range that predicts response to treatment as established with gastric cancer cell lines. Determination of predictive biomarkers by immunohistochemistry can be limited due to lack of high quality antibodies of sufficient specificity. Due to its high specificity, RNA in situ hybridization is a technique that can be used to confirm the findings obtained by immunohistochemistry and may potentially even replace immunohistochemistry it if no suitable antibodies are available or not specific enough e.g. to discriminate between closely related protein isoforms. We show the biological relevance of RNA in situ hybridization on FFPE samples by correlation with immunohistochemistry, ELISA based approaches and mass spectrometry. RNA ISH is shown to be specific and sensitive enough to identify cases of functionally relevant MET overexpression levels in gastric cancers and can be used to select patients for treatment.
Citation Format: Oliver von Ahsen, Thomas Krahn, Christoph Schatz. Validation of an antibody independent tool for patient selection: RNA in situ hybridization detects Met expression levels predictive for response to Met inhibition by Bay 853474. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 413.
Abstract 4130: A novel tumor-suppressor role for squalene epoxidase in human colorectal metastasis
Authors: Jun Soo Young , Cho Hyun-Soo , Lee Jeong-Ju , Yoon Ji-Yong , Ahn Jun-Ho , Min Ju-Sik , Jeon Sujin , Lee Jae-Hye , Choi Min Hyuk , Kim Nam-Soon 
Published: July 2016

Abstract
Malignancy cancer cells are reported to develop mechanisms to resist anoikis (apoptotic cell death from deprivation of cell-cell/matrix interactions), thereby enhancing the survival of cancer cells and secondary tumor formation in distant organs, which is responsible for 90% of cancer-related fatalities. A high serum level of cholesterol (hypercholesterolemia) in patients with colorectal cancers (CRCs) metastasis is reported, but the underlying relationship were never elucidated. Human CRC tissues revealed that the expression of squalene epoxidase (SqE), the rate-limiting enzyme in cholesterol synthesis, is significantly reduced in the advanced stages of CRC. Here we report that the knockdown/degradation of SqE by either the application of small-interfering RNA against SqE or a high-level of cholesterol significantly potentiates CRC cell survival/metastasis via the induction of an epithelial-mesenchymal transition as well as of anoikis resistance. We identified the interactions of SqE with glycogen synthase kinase 3β (GSK3β) and/or p53: SqE knockdown induced the dissociation of GSK3β and p53, thereby resulting in the downregulation of E-cadherin via the inhibition of GSK3 activity and of -catenin degradation, as well as the p53 degradation by the hdm2 upregulation. Overall, the present study demonstrates SqE is a key negative regulator of cancer cell survival and of CRC metastasis.
Citation Format: Soo Young Jun, Hyun-Soo Cho, Jeong-Ju Lee, Ji-Yong Yoon, Jun-Ho Ahn, Ju-Sik Min, Sujin Jeon, Jae-Hye Lee, Min Hyuk Choi, Nam-Soon Kim. A novel tumor-suppressor role for squalene epoxidase in human colorectal metastasis. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4130.